All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

UCSF Benioff Children’s Hospitals Rank Among Nation’s Best for 2025-2026

October 8th 2025

US News & World Report lists UCSF Health pediatric care as tied for best in Northern California, with three specialties among the top 10 nationwide.

FDA Issues CRL for Dasatinib in Chronic Myeloid Leukemia

October 8th 2025

The FDA has issued a CRL for dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.

Targeted Therapies Move the Needle in NSCLC

October 8th 2025

Benjamin P. Levy, MD, FASCO, discusses how new targeted approaches are affecting the NSCLC treatment landscape.

Melanoma Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 8th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in melanoma.

Personalization Drives Next Wave of Metastatic Castration-Sensitive Prostate Cancer Treatment

October 7th 2025

A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.

CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer

October 7th 2025

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ NSCLC

October 7th 2025

Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.

Dana-Farber Proposes Proton Therapy Center, Offering Leading Edge Treatment to Patients

October 7th 2025

Proton therapy provides pediatric patients a treatment option that minimizes impact on long-term growth and development.

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer

October 7th 2025

A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.

HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell Lymphoma

October 7th 2025

A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.

AI Integration and Systemic Reform Are Needed to Balance Resource Protection With Timely Access to Treatment

October 7th 2025

Emerging technologies and process reconsiderations may alleviate time and resource stressors oncology teams face when appealing patient insurance denials.

Linvoseltamab Demonstrates Potential for Early Intervention in High-Risk Smoldering Multiple Myeloma

October 7th 2025

Paula Rodriguez-Otero, MD, discusses linvoseltamab’s potential role in the management of high-risk smoldering myeloma.

FDA Approval of Intravesical Mitomycin in NMIBC Follows ODAC Debate on Need for Randomized Data

October 7th 2025

Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL

October 6th 2025

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.

Lung Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 6th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in lung cancer.

Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025

October 6th 2025

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

New Study Links Genetic Variation to Chemotherapy-Related Liver Damage in Patients With Colorectal Cancer Liver Metastases

October 6th 2025

A genetic factor may explain why some patients with colorectal cancer that has spread to the liver experience liver damage after chemotherapy.

First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC

October 6th 2025

Dato-DXd displayed topline survival benefits in patients with recurrent/metastatic TNBC who could not receive immunotherapy.

FDA Grants Priority Review to Orca-T for Hematologic Malignancies

October 6th 2025

The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.

Bevacizumab Plus Erlotinib Shows Antitumor Activity in Advanced Papillary Renal Cell Carcinoma

October 6th 2025

Phase 2 data showed bevacizumab plus erlotinib active in papillary RCC, with 72% responses in HLRCC-associated and 35% in sporadic disease.